Table 2.
Baseline Clinical Characteristics of Total Cohort (N=1838)
| Renin‐angiotensin system inhibitors (n=917) | Control (n=921) | |
|---|---|---|
| Mean age, y | 58.6 | 58.9 |
| Sex, n (%) | ||
| Male sex | 526/917 (57.4) | 532/921 (57.8) |
| Female sex | 391/917 (42.6) | 389/921 (42.2) |
| Past medical history, n (%) | ||
| Hypertension | 669/889 (75.3) | 679/897 (75.7) |
| Diabetes | 266/917 (29.0) | 258/921 (28.0) |
| Hypercholesterolemia | 115/329 (35.0) | 94/325 (28.9) |
| Cardiovascular disease | 90/856 (10.5) | 89/867 (10.2) |
| Obesity | 164/451 (36.4) | 159/450 (35.3) |
| Chronic kidney disease | 48/759 (6.3) | 44/763 (5.8) |
| Chronic obstructive pulmonary disease | 64/586 (10.9) | 61/572 (10.7) |
| Smoking, n (%) | ||
| Ever smoked | 109/514 (21.2) | 113/516 (21.9) |
| Nonsmoker | 405/514 (78.8) | 403/516 (78.1) |
| COVID‐19 severity, n (%) | ||
| Mild | 343/722 (47.5) | 324/709 (45.7) |
| Moderate | 311/722 (43.0) | 321/709 (45.3) |
| Severe | 68/722 (9.4) | 64/709 (9.0) |
Cardiovascular disease defined as established coronary artery disease, heart failure, arrythmia, and/or stroke; chronic kidney disease defined as estimated glomerular filtration rate <60 mL/min per 1.73 m2.